These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
255 related articles for article (PubMed ID: 10418856)
1. Insulin resistance and lipid metabolism. Howard BV Am J Cardiol; 1999 Jul; 84(1A):28J-32J. PubMed ID: 10418856 [TBL] [Abstract][Full Text] [Related]
2. [Disorders of lipid metabolism in insulin resistance]. Müller-Wieland D; Krone W Herz; 1995 Feb; 20(1):33-46. PubMed ID: 7713475 [TBL] [Abstract][Full Text] [Related]
3. Diabetic dyslipidemia. Kreisberg RA Am J Cardiol; 1998 Dec; 82(12A):67U-73U; discussion 85U-86U. PubMed ID: 9915665 [TBL] [Abstract][Full Text] [Related]
4. Dyslipidemia of the metabolic syndrome. Ruotolo G; Howard BV Curr Cardiol Rep; 2002 Nov; 4(6):494-500. PubMed ID: 12379172 [TBL] [Abstract][Full Text] [Related]
5. [Dyslipidemia in insulin resistance and its improvement by troglitazone]. Yagi K; Mabuchi H Nihon Rinsho; 2000 Feb; 58(2):426-9. PubMed ID: 10707570 [TBL] [Abstract][Full Text] [Related]
6. [Dyslipoproteinemia and metabolic syndrome. Effects of insulin resistance and hyperinsulinemia on lipid metabolism]. Krone W; Müller-Wieland D; Wirth H Fortschr Med; 1992 Dec; 110(34):645-8. PubMed ID: 1483617 [TBL] [Abstract][Full Text] [Related]
7. Lipoprotein physiology in nondiabetic and diabetic states. Relationship to atherogenesis. Ginsberg HN Diabetes Care; 1991 Sep; 14(9):839-55. PubMed ID: 1959476 [TBL] [Abstract][Full Text] [Related]
8. Dyslipidemias in patients with diabetes mellitus: classification and risks and benefits of therapy. Oki JC Pharmacotherapy; 1995; 15(3):317-37. PubMed ID: 7667166 [TBL] [Abstract][Full Text] [Related]
9. Postprandial dyslipidemia in men with visceral obesity: an effect of reduced LDL receptor expression? Mamo JC; Watts GF; Barrett PH; Smith D; James AP; Pal S Am J Physiol Endocrinol Metab; 2001 Sep; 281(3):E626-32. PubMed ID: 11500319 [TBL] [Abstract][Full Text] [Related]
10. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. DeFronzo RA; Ferrannini E Diabetes Care; 1991 Mar; 14(3):173-94. PubMed ID: 2044434 [TBL] [Abstract][Full Text] [Related]
11. Pathophysiology and treatment of the dyslipidemia of insulin resistance. Cohn G; Valdes G; Capuzzi DM Curr Cardiol Rep; 2001 Sep; 3(5):416-23. PubMed ID: 11504579 [TBL] [Abstract][Full Text] [Related]
12. Hypertriglyceridemia, atherogenic dyslipidemia, and the metabolic syndrome. Grundy SM Am J Cardiol; 1998 Feb; 81(4A):18B-25B. PubMed ID: 9526809 [TBL] [Abstract][Full Text] [Related]
13. Treatment of diabetic dyslipidemia. Garg A Am J Cardiol; 1998 Feb; 81(4A):47B-51B. PubMed ID: 9526814 [TBL] [Abstract][Full Text] [Related]
14. Cardiovascular risk continuum: implications of insulin resistance and diabetes. Hsueh WA; Law RE Am J Med; 1998 Jul; 105(1A):4S-14S. PubMed ID: 9707262 [TBL] [Abstract][Full Text] [Related]